EyePoint drug fails pivotal trial, company loses nearly $1 billion in market value

EyePoint lost nearly $1 billion in market value on August 17, 2026, after its lead drug candidate Duravyu failed to meet the primary non-inferiority endpoint in the Phase 3 LUGANO trial for wet age-related macular degeneration. EyePoint blamed the failure on an asymmetric cohort of nine patients with unrelated vision loss. The company's stock plummeted 70%, while competitor Ocular Therapeutix saw its shares rise. EyePoint's regulatory hopes now rest on the upcoming LUCIA trial results due in late 2026.

LUGANO trial failure

• ▪The LUGANO trial enrolled approximately 400 patients with wet age-related macular degeneration to compare EyePoint's Duravyu against aflibercept over a period of slightly more than one year.
• ▪EyePoint's experimental drug Duravyu failed to meet its primary goal of proving non-inferiority to aflibercept in the Phase 3 LUGANO clinical trial.

Cohort imbalance analysis

• ▪An ad hoc analysis by EyePoint indicated that Duravyu would have achieved non-inferiority to aflibercept in the LUGANO trial if the nine-patient asymmetric cohort had been excluded.
• ▪EyePoint attributed the LUGANO trial failure to an asymmetric cohort of nine patients in the Duravyu group who experienced vision loss unrelated to wet age-related macular degeneration.

Market value collapse

• ▪EyePoint's stock price plummeted by 70% by mid-morning on August 17, 2026, wiping out nearly $1 billion in market value following the LUGANO trial announcement.
• ▪The stock price of Ocular Therapeutix, a competitor developing a rival eye treatment, rose in response to EyePoint's clinical trial failure on August 17, 2026.

LUCIA trial importance

• ▪Mizuho Securities analyst Graig Suvannavejh stated that the LUCIA trial is the swing factor that could substantially de-risk Duravyu or prove far more problematic if it also misses.
• ▪EyePoint's future regulatory plans depend on the outcome of its second late-stage clinical trial, LUCIA, with results expected between October and December 2026.

Regulatory approval uncertainty

• ▪EyePoint CEO Jay Duker stated that the company may file for Food and Drug Administration approval of Duravyu in the first half of 2027, depending on the LUCIA trial results.
• ▪RBC Capital Markets analyst Lisa Walter noted that it will be challenging for the Food and Drug Administration to approve Duravyu without two positive non-inferiority trials.

Wet AMD treatment competition

• ▪EyePoint's Duravyu is designed to maintain vision in wet age-related macular degeneration patients with fewer injections than currently approved treatments like Eylea, Lucentis, Vabysmo, and Beovu.
• ▪Ocular Therapeutix plans to submit its competing wet age-related macular degeneration treatment to the Food and Drug Administration later in 2026.

2 sources